| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenue | 3,299 | 1,777 | 1,455 | 4,346 |
| Cost of revenue | 538 | 515 | 506 | 654 |
| Research and development | 13,028 | 11,449 | 11,584 | 5,956 |
| General and administrative | 4,871 | 5,386 | 6,139 | 5,653 |
| Licensing | 1,911 | 1,335 | 1,010 | 1,754 |
| Revaluation of contingent consideration | 100 | 1,500 | 300 | 800 |
| Total costs and expenses | 20,448 | 20,185 | 19,539 | 14,817 |
| Loss from operations | -17,149 | -18,408 | -18,084 | -10,471 |
| Interest income | 1,819 | 2,018 | 2,166 | 1,991 |
| Non-cash royalty income | 716 | 961 | 833 | 894 |
| Total other income | 2,535 | 2,979 | 2,999 | 2,885 |
| Net loss | -14,614 | -15,429 | -15,085 | -7,586 |
| Unrealized gain on marketable securities, net of tax of 0 | 115 | 48 | 337 | 890 |
| Total other comprehensive income | 115 | 48 | 337 | 890 |
| Comprehensive loss | -14,499 | -15,381 | -14,748 | -6,696 |
| Earnings per share, basic | -0.12 | -0.13 | -0.12 | -0.11 |
| Earnings per share, diluted | -0.12 | -0.13 | -0.12 | -0.11 |
| Weighted average number of shares outstanding, basic | 122,619,311 | 122,580,967 | 122,390,303 | 71,381,731 |
| Weighted average number of shares outstanding, diluted | 122,619,311 | 122,580,967 | 122,390,303 | 71,381,731 |
Aclaris Therapeutics, Inc. (ACRS)
Aclaris Therapeutics, Inc. (ACRS)